Implementation of Pharmacogenetic Testing in Hospital Wards

NCT ID: NCT04573491

Last Updated: 2023-03-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-05

Study Completion Date

2021-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone.

The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward.

The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Admitted Multimorbid Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacogenetic test

Medication review including results from pharmacogenetic testing

Group Type EXPERIMENTAL

Pharmacogenetic test

Intervention Type GENETIC

genotyping for genes that affect drug metabolism

Medication review

Intervention Type OTHER

systematic and interdisciplinary method aiming to increase quality of medication treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacogenetic test

genotyping for genes that affect drug metabolism

Intervention Type GENETIC

Medication review

systematic and interdisciplinary method aiming to increase quality of medication treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 2 long-term conditions
* at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
* at least 2 years life expectancy
* able to communicate in Norwegian
* able to give informed consent
* summary care record

Exclusion Criteria

* moderate to severe dementia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Akershus

OTHER

Sponsor Role collaborator

Diakonhjemmet Hospital

OTHER

Sponsor Role collaborator

University of Oslo School of Pharmacy

OTHER

Sponsor Role collaborator

Hospital Pharmacy Enterprise, South Eastern Norway

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathrin Bjerknes, Ph.D

Role: STUDY_DIRECTOR

Hospital Pharmacy Enterprise, South Eastern Norway

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Akershus University Hospital

Lørenskog, Nordbyhagen, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

References

Explore related publications, articles, or registry entries linked to this study.

Hjemas BJ, Bovre K, Bjerknes K, Mathiesen L, Mellingsaeter MCR, Molden E. Implementation of pharmacogenetic testing in medication reviews in a hospital setting. Br J Clin Pharmacol. 2023 Oct;89(10):3116-3125. doi: 10.1111/bcp.15815. Epub 2023 Jun 22.

Reference Type DERIVED
PMID: 37277227 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IMP-CYP SA HF 2020-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effectiveness of "Medisinstart"
NCT02261402 COMPLETED NA